Novo Nordisk’s Obesity Drug Shortage: Crunch Expands To First Gen Med Saxenda Amid Increased Demand
While Novo Nordisk A/S (NYSE: NVO) is still struggling with a shortage of its popular obesity medicine Wegovy (semaglutide), another weight loss drug has also made it to the FDA's list of drugs